Reports emerged on August 3 regarding a potential $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb. The potential deal faced skepticism from analysts due to significant regulatory hurdles in the oncology sector and concerns over the strategic rationale. However, by August 5, a senior source informed Reuters that there are no ongoing discussions between the two pharmaceutical giants regarding a potential deal.
A senior source confirmed to Reuters that no merger talks are underway between the pharmaceutical giants, quashing recent market speculation.
Read the full storyAnalysts express skepticism over the strategic rationale of a mega-merger facing intense antitrust hurdles in oncology.
In a move that could reshape the global healthcare landscape, Bristol Myers Squibb shares surged following reports of preliminary merger talks with AstraZeneca.